Form 4: Corcept CEO Sells 40,000 Shares Under 10b5-1 Plan

Corcept Therapeutics CEO Joseph K. Belanoff sold 40,000 shares of common stock in early October 2025 through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Joseph K. Belanoff, Chief Executive Officer and Director of Corcept Therapeutics Inc. (CORT), reported the sale of 40,000 shares of common stock.
• The sales occurred on October 1, 2025, through three separate transactions.
• The shares were sold at weighted average prices of $84.2895, $85.164, and $85.6662 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Belanoff on November 26, 2024.
• Following these sales, Mr. Belanoff indirectly beneficially owns 2,781,370 shares through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust.

Sentiment

Score: 4

Explanation: The sale of a significant number of shares by the CEO, even under a pre-arranged plan, can be interpreted with slight negative sentiment as it reduces the executive's direct equity exposure to the company. However, the 10b5-1 plan mitigates the immediate negative signal of an unplanned sale.

Negatives

• The sale of a significant number of shares (40,000) by the Chief Executive Officer, even under a pre-arranged plan, could be perceived negatively by some investors, potentially signaling a reduction in personal exposure to the company's equity.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The reported transactions involve shares held indirectly by Joseph K. Belanoff through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, which is considered a related party.

Stakeholder Impact

• Shareholders may perceive the CEO's sale of a substantial number of shares as a signal, potentially influencing their investment decisions, despite the pre-arranged nature of the sale.

Key Dates

Recommendation

While the sale of 40,000 shares by the CEO is notable, it was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned diversification or liquidity event rather than an immediate reaction to new negative information. Without additional context on the company's performance or strategic direction, this transaction alone does not warrant a 'sell' recommendation. Investors should 'hold' and monitor future company announcements and financial results for a more comprehensive view.

Keywords

Corcept Therapeutics, CORT, Joseph K. Belanoff, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Equity Transaction